CORCEPT THERAPEUTICS INC Comprehensive Income
CORCEPT THERAPEUTICS INC (CORT) reported Comprehensive Income of $42.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $42.51M, a 15.67% increase year-over-year.
- CORCEPT THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$33.11M, a 254.30% decline year-over-year.
- CORCEPT THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $24.21M, a 16.39% decline year-over-year.
- CORCEPT THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $19.72M, a 59.51% decline year-over-year.
- CORCEPT THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $102.13M, a 27.25% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $140.38M, a 30.45% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was $107.62M, a 6.79% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $100.78M, a 9.92% decline from fiscal 2021.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.51M 10-Q · filed 2026-07-29 | $9.40M 10-Q · filed 2026-07-29 | $33.61M derived: sum of 3 quarters · filed 2026-07-29 | $53.33M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$33.11M 10-Q · filed 2026-04-30 | -$8.90M derived: sum of 2 quarters · filed 2026-04-30 | $10.82M derived: sum of 3 quarters · filed 2026-04-30 | $47.57M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $24.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $43.93M derived: sum of 2 quarters · filed 2026-02-24 | $80.68M derived: sum of 3 quarters · filed 2026-07-29 | $102.13M 10-K · filed 2026-02-24 |
| 2025-09-30 | $19.72M 10-Q · filed 2025-11-04 | $56.47M derived: sum of 2 quarters · filed 2026-07-29 | $77.92M 10-Q · filed 2025-11-04 | $106.88M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $36.75M 10-Q · filed 2026-07-29 | $58.20M 10-Q · filed 2026-07-29 | $87.16M derived: sum of 3 quarters · filed 2026-07-29 | $135.86M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $21.46M 10-Q · filed 2026-04-30 | $50.41M derived: sum of 2 quarters · filed 2026-04-30 | $99.11M derived: sum of 3 quarters · filed 2026-04-30 | $134.43M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $28.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $77.66M derived: sum of 2 quarters · filed 2026-02-24 | $112.97M derived: sum of 3 quarters · filed 2026-02-24 | $140.38M 10-K · filed 2026-02-24 |
| 2024-09-30 | $48.70M 10-Q · filed 2025-11-04 | $84.01M derived: sum of 2 quarters · filed 2025-11-04 | $111.42M 10-Q · filed 2025-11-04 | $143.62M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $35.31M 10-Q · filed 2025-07-31 | $62.73M 10-Q · filed 2025-07-31 | $94.92M derived: sum of 3 quarters · filed 2026-02-24 | $126.02M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $27.41M 10-Q · filed 2025-05-05 | $59.61M derived: sum of 2 quarters · filed 2026-02-24 | $90.71M derived: sum of 3 quarters · filed 2026-02-24 | $118.43M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $32.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $63.30M derived: sum of 2 quarters · filed 2026-02-24 | $91.02M derived: sum of 3 quarters · filed 2026-02-24 | $107.62M 10-K · filed 2026-02-24 |
| 2023-09-30 | $31.10M 10-Q · filed 2024-10-30 | $58.83M derived: sum of 2 quarters · filed 2024-10-30 | $75.42M 10-Q · filed 2024-10-30 | $93.53M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $27.73M 10-Q · filed 2024-07-29 | $44.32M 10-Q · filed 2024-07-29 | $62.43M derived: sum of 3 quarters · filed 2025-02-26 | $96.80M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $16.59M 10-Q · filed 2024-05-01 | $34.71M derived: sum of 2 quarters · filed 2025-02-26 | $69.08M derived: sum of 3 quarters · filed 2025-02-26 | $95.70M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $18.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $52.48M derived: sum of 2 quarters · filed 2025-02-26 | $79.10M derived: sum of 3 quarters · filed 2025-02-26 | $100.78M 10-K · filed 2025-02-26 |
| 2022-09-30 | $34.37M 10-Q · filed 2023-11-01 | $60.99M derived: sum of 2 quarters · filed 2023-11-01 | $82.66M 10-Q · filed 2023-11-01 | $114.37M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $26.62M 10-Q · filed 2023-08-02 | $48.30M 10-Q · filed 2023-08-02 | $80.01M derived: sum of 3 quarters · filed 2024-02-15 | $110.38M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $21.67M 10-Q · filed 2023-05-03 | $53.38M derived: sum of 2 quarters · filed 2024-02-15 | $83.75M derived: sum of 3 quarters · filed 2024-02-15 | $110.24M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $31.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $62.08M derived: sum of 2 quarters · filed 2024-02-15 | $88.57M derived: sum of 3 quarters · filed 2024-02-15 | $111.87M 10-K · filed 2024-02-15 |
| 2021-09-30 | $30.37M 10-Q · filed 2022-11-03 | $56.86M derived: sum of 2 quarters · filed 2022-11-03 | $80.16M 10-Q · filed 2022-11-03 | $105.99M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $26.49M 10-Q · filed 2022-08-04 | $49.79M 10-Q · filed 2022-08-04 | $75.62M derived: sum of 3 quarters · filed 2023-02-28 | $96.98M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $23.30M 10-Q · filed 2022-05-05 | $49.13M derived: sum of 2 quarters · filed 2023-02-28 | $70.49M derived: sum of 3 quarters · filed 2023-02-28 | $99.35M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $25.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $47.19M derived: sum of 2 quarters · filed 2023-02-28 | $76.05M derived: sum of 3 quarters · filed 2023-02-28 | $106.17M 10-K · filed 2023-02-28 |
| 2020-09-30 | $21.36M 10-Q · filed 2021-11-03 | $50.22M derived: sum of 2 quarters · filed 2021-11-03 | $80.33M 10-Q · filed 2021-11-03 | $109.66M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $28.86M 10-Q · filed 2021-07-29 | $58.97M 10-Q · filed 2021-07-29 | $88.30M derived: sum of 3 quarters · filed 2022-02-15 | $114.63M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $30.11M 10-Q · filed 2021-05-06 | $59.44M derived: sum of 2 quarters · filed 2022-02-15 | $85.78M derived: sum of 3 quarters · filed 2022-02-15 | $106.19M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $29.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $55.66M derived: sum of 2 quarters · filed 2022-02-15 | $76.07M derived: sum of 3 quarters · filed 2022-02-15 | $94.51M 10-K · filed 2022-02-15 |
| 2019-09-30 | $26.33M 10-Q · filed 2020-11-03 | $46.75M derived: sum of 2 quarters · filed 2020-11-03 | $65.18M 10-Q · filed 2020-11-03 | $87.27M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $20.41M 10-Q · filed 2020-08-04 | $38.85M 10-Q · filed 2020-08-04 | $60.94M derived: sum of 3 quarters · filed 2021-02-23 | $78.74M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $18.44M 10-Q · filed 2020-05-04 | $40.53M derived: sum of 2 quarters · filed 2021-02-23 | $58.33M derived: sum of 3 quarters · filed 2021-02-23 | $76.55M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $22.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $39.89M derived: sum of 2 quarters · filed 2021-02-23 | $58.11M derived: sum of 3 quarters · filed 2021-02-23 | $75.42M 10-K · filed 2021-02-23 |
| 2018-09-30 | $17.80M 10-Q · filed 2019-11-07 | $36.02M derived: sum of 2 quarters · filed 2019-11-07 | $53.33M 10-Q · filed 2019-11-07 | $151.59M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $18.22M 10-Q · filed 2019-08-01 | $35.53M 10-Q · filed 2019-08-01 | $133.80M derived: sum of 3 quarters · filed 2020-02-24 | $147.56M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $17.31M 10-Q · filed 2019-05-09 | $115.58M derived: sum of 2 quarters · filed 2020-02-24 | $129.34M derived: sum of 3 quarters · filed 2020-02-24 | $141.98M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $98.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $112.03M derived: sum of 2 quarters · filed 2020-02-24 | $124.67M derived: sum of 3 quarters · filed 2020-02-24 | $129.05M 10-K · filed 2020-02-24 |
| 2017-09-30 | $13.76M 10-Q · filed 2018-11-02 | $26.40M derived: sum of 2 quarters · filed 2018-11-02 | $30.78M 10-Q · filed 2018-11-02 | $35.38M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $12.64M 10-Q · filed 2018-08-09 | $17.02M 10-Q · filed 2018-08-09 | $21.61M derived: sum of 3 quarters · filed 2019-02-26 | $24.20M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $4.38M 10-Q · filed 2018-05-09 | $8.97M derived: sum of 2 quarters · filed 2019-02-26 | $11.56M derived: sum of 3 quarters · filed 2019-02-26 | $12.54M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $7.18M derived: sum of 2 quarters · filed 2019-02-26 | $8.16M derived: sum of 3 quarters · filed 2019-02-26 | $8.14M 10-K · filed 2019-02-26 |
| 2016-09-30 | $2.58M 10-Q · filed 2017-11-03 | $3.56M derived: sum of 2 quarters · filed 2017-11-03 | $3.54M 10-Q · filed 2017-11-03 | |
| 2016-06-30 | $977.00K 10-Q · filed 2017-08-02 | $958.00K 10-Q · filed 2017-08-02 | ||
| 2016-03-31 | -$19.00K 10-Q · filed 2017-05-02 | |||
| 2015-12-31 | -$6.41M 10-K · filed 2018-02-28 | |||
| 2014-12-31 | -$31.38M 10-K · filed 2015-03-13 | |||
| 2013-12-31 | -$46.01M 10-K · filed 2015-03-13 | |||
| 2012-12-31 | -$38.05M 10-K · filed 2015-03-13 | |||
| 2011-12-31 | -$32.35M 10-K · filed 2014-03-14 | |||
| 2010-12-31 | -$25.97M 10-K · filed 2013-03-15 | |||
| 2009-12-31 | -$20.16M 10-K · filed 2012-03-13 | |||
| 2008-12-31 | -$20.07M 10-K · filed 2012-03-13 | |||
| 2007-12-31 | -$11.57M 10-K · filed 2012-03-13 | |||
| 2006-12-31 | -$24.77M 10-K · filed 2012-03-13 | |||
| 2005-12-31 | -$20.14M 10-K · filed 2012-03-13 | |||
| 2004-12-31 | -$15.60M 10-K · filed 2012-03-13 | |||
| 2003-12-31 | -$9.81M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |